Literature DB >> 20854910

Highly efficient production of phosphorylated hepatitis B core particles in yeast Pichia pastoris.

Janis Freivalds1, Andris Dislers, Velta Ose, Paul Pumpens, Kaspars Tars, Andris Kazaks.   

Abstract

Virus-like particles (VLPs) of the recombinant hepatitis B virus (HBV) core protein (HBc) are routinely used in HBV diagnostics worldwide and are of potential interest as carriers of foreign peptides (e.g., immunological epitopes and targeting addresses, and/or as vessels for packaged diagnostic and therapeutic nanomaterials). Despite numerous reports exploiting different expression systems, a rapid and comprehensive large-scale methodology for purification of HBc VLPs from yeast is still lacking. Here, we present a convenient protocol for highly efficient production and rapid purification of endotoxin-free ayw subtype HBc VLPs from the methylotrophic yeast Pichia pastoris. The HBc gene expression cassette along with the geneticin resistance gene was transferred to the P. pastoris genome via homologous recombination. A producer clone was selected among 2000 transformants for the optimal synthesis of the target protein. Fermentation conditions were established ensuring biomass accumulation of 163g/L. A simple combination of pH/heat and salt treatment followed by a single anion-exchange chromatography step resulted in a more than 90% pure preparation of HBc VLPs, with a yield of about 3.0mg per 1g of wet cells. Purification is performed within a day and may be easily scaled up if necessary. The quality of HBc VLPs was verified by electron microscopy. Mass spectrometry analysis and direct polyacrylamide gel staining revealed phosphorylation of HBc at at least two sites. To our knowledge, this is the first report of HBc phosphorylation in yeast.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854910     DOI: 10.1016/j.pep.2010.09.010

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  17 in total

1.  Expression and purification of virus like particles (VLPs) of foot-and-mouth disease virus in Eri silkworm (Samia cynthia ricini) larvae.

Authors:  Manoj Kumar; P Saravanan; S K Jalali
Journal:  Virusdisease       Date:  2015-11-24

2.  Yeast-expressed bacteriophage-like particles for the packaging of nanomaterials.

Authors:  Janis Freivalds; Svetlana Kotelovica; Tatyana Voronkova; Velta Ose; Kaspars Tars; Andris Kazaks
Journal:  Mol Biotechnol       Date:  2014-02       Impact factor: 2.695

3.  Secreted recombinant P53 protein from Pichia pastoris is a useful antigen for detection of serum p53: autoantibody in patients with advanced colorectal adenocarcinoma.

Authors:  Salma Abdelmoula-Souissi; Nourane Zouari; Imen Miladi-Abdenadher; Ouhoud Yaich-Kolsi; Ines Ayadi-Masmoudi; Abdelmajid Khabir; Hatem Masmoudi; Mounir Frikha; Raja Mokdad-Gargouri
Journal:  Mol Biol Rep       Date:  2013-03-26       Impact factor: 2.316

4.  Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.

Authors:  Arnis Strods; Velta Ose; Janis Bogans; Indulis Cielens; Gints Kalnins; Ilze Radovica; Andris Kazaks; Paul Pumpens; Regina Renhofa
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

5.  Escherichia coli-derived virus-like particles in vaccine development.

Authors:  Xiaofen Huang; Xin Wang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  NPJ Vaccines       Date:  2017-02-09       Impact factor: 7.344

6.  Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.

Authors:  Andris Kazaks; I-Na Lu; Sophie Farinelle; Alex Ramirez; Vincenzo Crescente; Benjamin Blaha; Olotu Ogonah; Tarit Mukhopadhyay; Mapi Perez de Obanos; Alejandro Krimer; Inara Akopjana; Janis Bogans; Velta Ose; Anna Kirsteina; Tatjana Kazaka; Nicola J Stonehouse; David J Rowlands; Claude P Muller; Kaspars Tars; William M Rosenberg
Journal:  BMC Biotechnol       Date:  2017-11-10       Impact factor: 2.563

7.  Cost-effective purification process development for chimeric hepatitis B core (HBc) virus-like particles assisted by molecular dynamic simulation.

Authors:  Bingyang Zhang; Shuang Yin; Yingli Wang; Zhiguo Su; Jingxiu Bi
Journal:  Eng Life Sci       Date:  2021-05-03       Impact factor: 2.678

8.  A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice.

Authors:  Irina Sominskaya; Dace Skrastina; Ivars Petrovskis; Andris Dishlers; Ieva Berza; Maria Mihailova; Juris Jansons; Inara Akopjana; Irina Stahovska; Dzidra Dreilina; Velta Ose; Paul Pumpens
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

9.  The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.

Authors:  Andris Dishlers; Dace Skrastina; Regina Renhofa; Ivars Petrovskis; Velta Ose; Ilva Lieknina; Juris Jansons; Paul Pumpens; Irina Sominskaya
Journal:  Mol Biotechnol       Date:  2015-12       Impact factor: 2.695

10.  Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity.

Authors:  Andrew G Diamos; Mary D Pardhe; Haiyan Sun; Joseph G L Hunter; Tsafrir Mor; Lydia Meador; Jacquelyn Kilbourne; Qiang Chen; Hugh S Mason
Journal:  Vaccine       Date:  2020-03-12       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.